S&P Global: Additional $1.3 Billion ASR to Be Launched in Coming Weeks
S&P Global: Additional $1.3 Billion ASR to Be Launched in Coming Weeks.
S&P Global: Additional $1.3 Billion ASR to Be Launched in Coming Weeks Read Post »
S&P Global: Additional $1.3 Billion ASR to Be Launched in Coming Weeks.
S&P Global: Additional $1.3 Billion ASR to Be Launched in Coming Weeks Read Post »
Starbucks Executive Said Fall Season Launch Led To Record-breaking Average Weekly Sales; 90-day Active Rewards Members Reached Record Of Nearly 33M In Q4; Set Records In Spend Per Member, Total Member Spend -Conf Call.
Starbucks Executive Said Fall Season Launch Led To Record-breaking Average Weekly Sales Read Post »
Eli Lilly and Company (LLY) reported Q3 non-GAAP earnings Thursday of $0.10 per diluted share, down from $1.98 a year earlier. Analysts polled by Capital IQ expected $0.67. Revenue for the quarter ended Sept. 30 was $9.50 billion, up from $6.94 billion a year earlier. Analysts surveyed by Capital IQ expected $8.99 billion. The company lowered 2023 guidance for non-GAAP earnings to $6.50 and $6.70 per share, from $9.70 to $9.90 previously. Analysts surveyed by Capital IQ expect $7.97. The drug maker also continues to expect revenue of $33.4 billion and $33.9 billion. Analysts surveyed by Capital IQ expect $33.42 billion.
Eli Lilly Q3 Non-GAAP Earnings Fall, Revenue Rises; Lowers Full-Year EPS Guidance Read Post »
S&P Global posted higher sales and earnings for the third quarter, lifted by strength across the data-and-analytics company. The New York-based credit-ratings and data provider reported a profit of $742 million, or $2.33 a share, up from $608 million, or $1.84 a share, in the same quarter a year ago. Stripping out one-time items, adjusted earnings were $3.21 a share. Analysts surveyed by FactSet expected adjusted earnings of $3.04 a share. Sales rose 8% to $3.08 billion. Analysts surveyed by FactSet expected $3.03 billion. Sales rose across all of the company’s businesses, excluding its engineering-solutions business, which it has agreed to sell for $975 million to private-equity buyers. S&P Global’s ratings business recorded a 20% rise in sales and its market-intelligence unit posted an 8% increase in sales.
S&P Global Global Posts Higher Revenue Read Post »
S&P Global Reiterates 2023 GAAP Revenue Guidance; Narrows Adjusted Revenue Growth Forecast From 4%-6% To 4.5%-5.5%。
Starbucks Executive Said China’s Average Weekly Sales Grew Quarter Over Quarter In Line With Our Guidance Of Low To Mid Single Digit Growth -Conf Call。
Starbucks Executive Said We Expect Fiscal Year 2024 Global Comp Growth To Be 5% To 7% -Conf Call。
Starbucks Executive Said China FY2024 Comp Sales Expected To Be In The Range Of 4% To 6% In Q2 Through Q4 -Conf Call。
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: ROKU benefits on the pivot to video streaming from pay TV. The bull case scenario seems to be a low threshold of just reaching positive EBITDA in 2024. Assuming a high risk premium, we keep our target price at $75 on a forward P/S of 2.48x vs. media peers’ 2.0x average. We narrow our LPS in 2023 by $1.30 to -$3.50 and reduce 2024’s by $0.40 to -$2.40. ROKU posted a normalized loss of -$0.33 (GAAP loss of -$2.33) in Q3 2023 and adj. EBITDA was +43.4M, with guidance of +$10.0M in Q4 2023, which ROKU is steadfast on reaching positive EBITDA for the full year 2024. We forecast total revenue of $3.44B in 2023 and $3.82B in 2024. Platform unit realized 18% Y/Y revenue growth (86%
CFRA Keeps Hold Rating On Shares Of Roku, Inc. Read Post »
Estée Lauder Q1 Adj. EPS $0.11 Vs $(0.20) Est., Net Sales $3.52B Vs $3.529B Est.
Estée Lauder Q1 Adj. EPS $0.11 Vs $(0.20) Est., Net Sales $3.52B Vs $3.529B Est. Read Post »
Estée Lauder Sees FY24 Reported Net Sales Down 2% To Up 1%, Sees Adj. EPS Down 25-33% On Constant Currency Basis。
Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $300 to $291.
Morgan Stanley lowers Amgen (NASDAQ:AMGN) price target from $300 to $291 Read Post »